Remote Ontario-wide
Toronto, Ontario, Canada
NCT Number: NCT05454943
This study will evaluate the implementation and effectiveness of free-living TRE on biological and behavioural breast cancer risk factors.
Looking for future studies?
Notify Me50 year and older
Female
Interventional
Not applicable
Toronto, Ontario, Canada
TRE is an eating pattern where individuals consume ad libitum energy intake within a set window of time, commonly 8 hours, which induces a fasting window of 16 hours per day (i.e., 16:8 TRE). TRE is a simple and accessible lifestyle intervention with high adherence potential that may target both biological and behavioural mechanisms of breast cancer risk.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A standardized 16:8 TRE protocol with an 11 am to 7 pm eating window.
A personalized TRE protocol following pre-specified rules: 1) 8-10 hour eating window; 2) self-selected eating window start time as long as it ends ≥3h before bedtime; 3) if days off are required, aim to do so after following TRE for ≥5 successive days each week.
External support (from study staff) that includes consultation with a registered dietitian and ongoing tailored feedback via support calls at weeks 1, 3, 6, and 12.
Matched pairs will meet by phone/video at weeks 1, 3, 6, and 12.
Time frame: 16-week average
Assessed daily through twice daily automated text messages asking participants to respond with what time they started and stopped eating that day.
Time frame: 16 Weeks
Collected via venipuncture
Time frame: 16 Weeks
Homeostatic Model Assessment for Insulin Resistance calculated as fasting glucose in mmol/l*fasting insulin in μU/ml/22.5
Time frame: 16 Weeks
Participants will be provided with a Dexcom G6 continuous glucose monitor transmitter and sensor. This data will be evaluated as the 5-day average of: 24-hour, daytime, and nocturnal glucose concentration, time in hyper, normo and hypoglycemia, and glycemic variability
Time frame: 16 Weeks
Measured via venipuncture and core lab lab analysis
Time frame: 16 Weeks
Measured via venipuncture and core lab lab analysis
Time frame: 16 Weeks
Measured via Fitbit Aria Air scale at baseline and 16-weeks but also once per week to evaluate trajectory of change
Time frame: 16 weeks
Measured via provided circumference measuring tape as the average of 2 measurements
Time frame: 16 Weeks
Participant will be provided with a Bios 3al1-3e blood pressure measuring device. After 5 minutes of quiet seated rest, blood pressure will be measured 6 times, 60 seconds apart in a standardized seated position with the average of the 2nd through 6th measurement used.
Time frame: 16 Weeks
Calculated via both the Framingham and Reynolds 10-year CVD risk scores using measured collected for study purposes (i.e., age, total cholesterol, HDL, systolic blood pressure, smoking status, C-reactive protein, family history of heart disease).
Time frame: 16 Weeks
As defined by the NCEP/ATP III criteria using measurements taken using provided study tools
Time frame: 16 Weeks
As defined by the NCEP/ATP III criteria and age and ethnic specific calculations
Time frame: 16 Weeks
Measured via venipuncture and core lab lab analysis
Time frame: 16 Weeks
Evaluated via an 'End of Study Survey' (including a Diet Satisfaction Score Tool and acceptability questions) and semi-structured qualitative interviews
Time frame: 16 Weeks
Evaluated as uptake of each delivery model, defined as adherence to the intervention touch points (i.e., external support: support calls with staff; peer support: number of peer interactions; both: response rate to adherence).
Time frame: 16 Weeks
Intervention costs will be evaluated and averaged per participant from the time required for intervention phone calls, scheduling, and technical support for adherence app by the study staff according to hourly rates of pay.
Time frame: 1, 2, 3, and 4 months post intervention period
Evaluated via participant self-report of continued TRE post-intervention
Time frame: 16 Weeks
Measured via experience of selected relevant Common Terminology Criteria for Adverse Events (CTCAE v5) with additional questions about duration and change in the revised 18-item version of the Three-Factor Eating Questionnaire (aka Eating Inventory)
Time frame: 16 Weeks
Measured by the RAND-36 Physical Component Summary. Physical component summary of the RAND-36 questionnaire (minimum = 0, maximum = 50, a higher score is a better outcome)
Time frame: 16 Weeks
Measured via FitBit Inspire 2 as 7-day average
Time frame: 16 Weeks
Measured via FitBit Inspire 2 as 7-day average
Time frame: 16 Weeks
Measured via FitBit Inspire 2 as 7-day average
Time frame: 16 weeks
Evaluated via the Hospital Anxiety and Depression Scale (HADS); This 14-item questionnaire has a minimum score of 0 and maximum of 21, where a higher score is worse.
Time frame: 16 weeks
Evaluated via the Hospital Anxiety and Depression Scale (HADS); This 14-item questionnaire has a minimum score of 0 and maximum of 21, where a higher score is worse.
University of Toronto
Other
Proof-of-Concept of Time-Restricted Eating as a Novel Lifestyle Intervention for Breast Cancer Prevention
Acronym: READY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04266665
Brain Diseases, Brain Neoplasms
Thessaloniki, Greece
View Trial DetailsNCT05934422
Allergy, Atopic Dermatitis
Auckland, New Zealand
View Trial DetailsNCT05535582
Acute Coronary Syndrome, Acute Myocardial Infarction
Thessaloniki, Central Macedonia, Greece
View Trial DetailsNCT06292546
Gut Microbiota, Helicobacter Pylori Eradication
Xiamen, Fujian, China
View Trial Details